TABLE 1

In Vitro Binding of ¹²³I-mAb 14C5 to Carcinoma Cells Compared with CA14C5 Expression and Biologic Activity (Cell Substrate Adhesion Inhibition) of Nonradiolabeled mAb 14C5

Cell line	Origin	CA14C5 expression*	Cell substrate adhesion inhibition^†	¹²³I-mAb 14C5 binding^‡ (%)
Cell line	Origin	CA14C5 expression*	Cell substrate adhesion inhibition^†			Average	SD
SK-BR-3	Breast adenocarcinoma	+++	+++	3.91	0.08
T47D	Breast carcinoma	+	+	0.10	0.02
791T	Skeletal osteosarcoma	+	−	0.15	0.01
HeLa	Cervical spinocellular carcinoma	+++	+	2.26	0.24
CoLo-16	Skin spinocellular carcinoma	−	−	0.07	0.02

↵* CA14C5 expression based on previously performed immunohistochemical and fluorescent staining experiments (25,26).
↵^† Inhibitory effect of nonradiolabeled mAb 14C5 on cell substrate adhesion as demonstrated by earlier reported adhesion inhibition experiments on artificial substrates in vitro (13,14,25).
↵^‡ Values represent percentage of specific ¹²³I-mAb 14C5 binding to each carcinoma cell type (total bound minus nonspecifically bound) as determined by Equation 1 (n = 6).